SCHEMBL6093906

SCHEMBL6093906

Cc1cc(CNC(=O)c2nc(N3CCN(c4ccccn4)CC3)n(C)c(=O)c2O)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
ADRB2 P07550 1/20 0.43
STAT6 P42226 1/20 0.43
HTT P42858 1/20 0.43
HIF1A Q16665 1/20 0.43
MMP13 P45452 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
CHRNA7 P36544 1/20 0.40
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096003 0.91 MMP13 (0.45) GRM5KDM4EALDH1A1MMP13KCNE1
SCHEMBL6093740 0.89 MEN1 (0.48) L3MBTL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL6094922 0.88 MMP13 (0.43) SMN1; SMN2KDM4EALDH1A1LMNAMMP13
SCHEMBL6093967 0.87 MMP13 (0.47) SMN1; SMN2KDM4EALDH1A1LMNAMMP13
SCHEMBL6094909 0.85 MMP13 (0.44) ALDH1A1MMP13KCNE1CCR1KCNQ1
SCHEMBL6095046 0.85 MMP13 (0.43) KDM4EALDH1A1MMP13MEN1KMT2A
SCHEMBL6094065 0.85 MMP13 (0.45) MMP13MEN1KMT2AKCNE1CCR1
SCHEMBL6094348 0.85 MMP13 (0.44) MMP13MEN1KMT2AKCNE1CCR1
SCHEMBL6095011 0.85 MMP13 (0.44) LMNAMMP13CYP3A4KCNE1CCR1
SCHEMBL6093733 0.85 SOS1 (0.47) MMP13KCNE1CCR1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US claimed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 GRM5 4021/4885L3MBTL1 189/4885SMN1; SMN2 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.